US Stock MarketDetailed Quotes
CSBR Champions Oncology
- 9.780
- -0.170-1.71%
Close Jan 17 16:00 ET
- 9.780
- 0.0000.00%
Post 16:00 ET
135.15MMarket Cap-195.60P/E (TTM)
10.184High9.771Low30.53KVolume10.140Open9.950Pre Close303.29KTurnover0.59%Turnover RatioLossP/E (Static)13.82MShares10.90052wk High199.59P/B51.07MFloat Cap3.60052wk Low--Dividend TTM5.22MShs Float25.800Historical High--Div YieldTTM4.15%Amplitude0.072Historical Low9.935Avg Price1Lot Size
Champions Oncology Key Stats
Quarterly+Annual
YOY
| (Q2)Oct 31, 2024 | (Q1)Jul 31, 2024 | (FY)Apr 30, 2024 | (Q4)Apr 30, 2024 | (Q3)Jan 31, 2024 | (Q2)Oct 31, 2023 | (Q1)Jul 31, 2023 | (FY)Apr 30, 2023 | (Q4)Apr 30, 2023 | (Q3)Jan 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -148.05%-283K | 107.79%311K | -254.51%-6.14M | -162.43%-1.82M | -158.42%-919K | -82.08%589K | -1,946.67%-3.99M | -38.86%3.97M | -186.93%-692K | -63.05%1.57M |
| Net income from continuing operations | 135.15%728K | 151.17%1.31M | -36.38%-7.28M | 95.74%-109K | -3.73%-2.53M | -12,843.75%-2.07M | -704.39%-2.57M | -1,073.54%-5.34M | -644.48%-2.56M | -409.91%-2.44M |
| Operating gains losses | ---- | ---- | --435K | --354K | --16K | ---- | ---- | ---- | ---- | ---- |
| Depreciation and amortization | -17.56%399K | 0.90%449K | -16.87%1.87M | -21.61%457K | -16.35%481K | -13.57%484K | -15.72%445K | 38.05%2.25M | 2.64%583K | 45.20%575K |
| Other non cash items | 26.72%294K | 7.04%289K | 11.97%1.07M | 110.37%284K | 1.82%280K | -15.02%232K | 0.37%270K | 21.12%952K | -46.22%135K | 1,618.75%275K |
| Change In working capital | -185.75%-1.5M | 29.28%-1.93M | -190.10%-3.82M | -13,545.83%-3.23M | -86.97%375K | -20.99%1.75M | -210.01%-2.73M | 81.64%4.24M | 157.14%24K | 4.73%2.88M |
| -Change in receivables | -206.68%-1.23M | 151.41%565K | -252.22%-1.99M | -2,500.00%-1.79M | -126.51%-250K | 317.39%1.15M | -795.57%-1.1M | 146.42%1.31M | 93.87%-69K | 353.49%943K |
| -Change in prepaid assets | 21.23%394K | 8.07%241K | 9.24%-167K | 0.90%-660K | -131.98%-55K | 162.10%325K | 19.89%223K | 1.60%-184K | -14.04%-666K | 0.58%172K |
| -Change in payables and accrued expense | 81.02%-245K | -355.28%-628K | -84.66%356K | -39.20%774K | 1,083.02%627K | -172.49%-1.29M | 131.26%246K | 100.52%2.32M | 410.49%1.27M | -86.09%53K |
| -Change in other current assets | --0 | --0 | ---169K | --1K | ---1K | --0 | ---169K | --0 | --0 | --0 |
| -Change in other current liabilities | -29.18%-332K | -10.62%-323K | -28.89%-1.17M | -136.36%-312K | -16.67%-308K | 1.53%-257K | -16.80%-292K | -43.74%-907K | 54.95%-132K | -26,300.00%-264K |
| -Change in other working capital | -105.04%-92K | -9.06%-1.78M | -140.04%-683K | -223.56%-1.24M | -81.66%362K | 508.33%1.83M | -778.49%-1.63M | -64.57%1.71M | -116.12%-382K | -23.16%1.97M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -148.05%-283K | 107.79%311K | -254.51%-6.14M | -162.43%-1.82M | -158.42%-919K | -82.08%589K | -1,946.67%-3.99M | -38.86%3.97M | -186.93%-692K | -63.05%1.57M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -18.99%-94K | 0 | 70.89%-836K | 114.61%111K | 73.47%-200K | 86.92%-79K | 11.41%-668K | -20.47%-2.87M | -50.20%-760K | -86.17%-754K |
| Net PPE purchase and sale | -18.99%-94K | --0 | 70.89%-836K | 114.61%111K | 73.47%-200K | 86.92%-79K | 11.41%-668K | -20.47%-2.87M | -50.20%-760K | -86.17%-754K |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -18.99%-94K | --0 | 70.89%-836K | 114.61%111K | 73.47%-200K | 86.92%-79K | 11.41%-668K | -20.47%-2.87M | -50.20%-760K | -86.17%-754K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 78.36%239K | 93.73%-37K | -4,890.91%-527K | -93.33%-145K | 74K | 55.81%134K | -590K | -94.69%11K | -568.75%-75K | 0 |
| Net issuance payments of debt | 50.00%-37K | ---37K | ---146K | ---- | ---- | ---74K | --0 | --0 | ---- | ---- |
| Net common stock issuance | --0 | --0 | -756.76%-634K | --0 | --0 | ---32K | ---602K | ---74K | ---74K | --0 |
| Proceeds from stock option exercised by employees | 15.00%276K | --0 | 197.65%253K | 200.00%1K | --0 | 179.07%240K | --12K | -58.94%85K | -106.25%-1K | --0 |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 78.36%239K | 93.73%-37K | -4,890.91%-527K | -93.33%-145K | --74K | 55.81%134K | ---590K | -94.69%11K | -568.75%-75K | --0 |
| Net cash flow | ||||||||||
| Beginning cash position | -40.60%2.89M | -74.13%2.62M | 12.33%10.12M | -61.63%4.47M | -49.08%5.51M | -39.58%4.87M | 12.33%10.12M | 92.17%9.01M | 33.84%11.65M | 126.44%10.83M |
| Current changes in cash | -121.43%-138K | 105.22%274K | -775.07%-7.5M | -21.15%-1.85M | -227.59%-1.05M | -76.73%644K | -453.11%-5.25M | -74.28%1.11M | -599.02%-1.53M | -79.11%819K |
| End cash Position | -50.05%2.75M | -40.60%2.89M | -74.13%2.62M | -74.13%2.62M | -61.63%4.47M | -49.08%5.51M | -39.58%4.87M | 12.33%10.12M | 12.33%10.12M | 33.84%11.65M |
| Free cash flow | -173.92%-377K | 106.68%311K | -733.91%-6.97M | -17.42%-1.71M | -236.63%-1.12M | -80.98%510K | -390.94%-4.66M | -73.26%1.1M | -600.69%-1.45M | -78.74%819K |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion | -- | -- |
Heat List
US
Overall
Symbol
Price
% Chg
No Data